A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis

Study Identifier
P20-483
CT.gov Identifier
NCT04758117
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Psoriatic Arthritis (PsA)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of active Psoriatic Arthritis (PsA) upon judgment of the treating physician. * Swollen joint count (SJC) \>= 1 out of 66 joints. * Decision on the treatment with Upadacitinib was made prior to any decision to approach the participant to participate in this study.
    Exclusion Criteria:
    * Cannot be treated with Upadacitinib according to the local Upadacitinib Summary of Product Characteristics (SmPC). * Prior treatment with Upadacitinib. * Currently participating in interventional research or within the last 30 days.

    Protocol Summary

    Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by the body's immune system mistakenly attacking healthy joint tissue causing inflammation, joint damage, disability, and a reduced life expectancy. The main objective of this study is to characterize attainment of minimal disease activity (MDA) at week 24 under continuous treatment with upadacitinib in participants with oligo- or polyarticular PsA as part of real-world practice.

    Upadacitinib is a drug approved for the treatment of Psoriatic arthritis (PsA) in Germany and Canada. Approximately 380 adult participants with PsA at multiple sites in Germany and Canada.

    Participants will receive oral Upadacitinib tablets per current local label, according to local standard of care and international guidelines.

    There may be a higher burden for participants in this study compared to standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and by questionnaire.

    Study Locations

    Location
    Status
    Location
    Dr. Jonathan D. Chan Inc. /ID# 241611
    Vancouver, British Columbia, Canada, V5Z 1J9
    Status
    Not applicable
    Location
    Manitoba Clinic /ID# 234148
    Winnipeg, Manitoba, Canada, R3A 1M3
    Status
    Not applicable
    Location
    The Waterside Clinic /ID# 234146
    Barrie, Ontario, Canada, L4M 6L2
    Status
    Not applicable
    Location
    Dr. Chrisostomos Kouroukis & Dr. Pauline Boulos MPC /ID# 233565
    Dundas, Ontario, Canada, L9H 1B7
    Status
    Not applicable
    Location
    Arthur Karasik Medicine Professional Corporation /ID# 234147
    Etobicoke, Ontario, Canada, M9C 5N2
    Status
    Not applicable
    Location
    Lau Bacchus Professional Medicine Corp /ID# 245283
    Hamilton, Ontario, Canada, L8N 1Y2
    Status
    Not applicable
    Showing {first} - {last} of {total} Results